Researchers say discoveries could expand the CRISPR toolbox and lead to more efficient, rapid diagnostic tools for detecting COVID-19, influenza, and RSV.

Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey ...

-Positive Phase 1 data for CTX310 ® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of ...